Moomoo AI 已提取核心信息
Novo Nordisk A/S, a leading global healthcare company, has announced the continuation of its share repurchase program, which began on February 6, 2024. The program, compliant with the European Union's Market Abuse Regulation (MAR) and Safe Harbour Rules, is part of a larger 12-month buyback plan to repurchase shares worth up to DKK 20 billion. From February 26, 2024, to March 1, 2024, Novo Nordisk bought back 824,500 B shares at an average price of DKK 836.80 per share, totaling DKK 689,940,585. The transactions are part of a scheduled repurchase running until April 30, 2024, with a target of DKK 2.1 billion for this period. Following these purchases, Novo Nordisk holds 47,365,207 B shares as treasury shares, representing 1.1% of the share capital. The company, with a rich history dating back to 1923, is committed to combating serious chronic diseases and employs approximately 63,400 people across 80 countries. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
Novo Nordisk A/S, a leading global healthcare company, has announced the continuation of its share repurchase program, which began on February 6, 2024. The program, compliant with the European Union's Market Abuse Regulation (MAR) and Safe Harbour Rules, is part of a larger 12-month buyback plan to repurchase shares worth up to DKK 20 billion. From February 26, 2024, to March 1, 2024, Novo Nordisk bought back 824,500 B shares at an average price of DKK 836.80 per share, totaling DKK 689,940,585. The transactions are part of a scheduled repurchase running until April 30, 2024, with a target of DKK 2.1 billion for this period. Following these purchases, Novo Nordisk holds 47,365,207 B shares as treasury shares, representing 1.1% of the share capital. The company, with a rich history dating back to 1923, is committed to combating serious chronic diseases and employs approximately 63,400 people across 80 countries. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
全球领先的医疗保健公司诺和诺德A/S宣布继续其股票回购计划，该计划于2024年2月6日开始。该计划符合欧盟的《市场滥用条例》（MAR）和《安全港规则》，是为期12个月的更大规模回购计划的一部分，该计划旨在回购价值高达200亿丹麦克朗的股票。从2024年2月26日到2024年3月1日，诺和诺德以每股836.80丹麦克朗的平均价格回购了824,500股B股，总额为689,940,585丹麦克朗。这些交易是2024年4月30日之前的计划回购的一部分，该期间的目标是21亿丹麦克朗。在这些收购之后，诺和诺德持有47,365,207亿股股票作为库存股，占股本的1.1％。该公司的悠久历史可以追溯到1923年，致力于抗击严重的慢性病，在80个国家拥有约63,400名员工。诺和诺德的股票在哥本哈根纳斯达克上市，其ADR在纽约证券交易所上市。
全球领先的医疗保健公司诺和诺德A/S宣布继续其股票回购计划，该计划于2024年2月6日开始。该计划符合欧盟的《市场滥用条例》（MAR）和《安全港规则》，是为期12个月的更大规模回购计划的一部分，该计划旨在回购价值高达200亿丹麦克朗的股票。从2024年2月26日到2024年3月1日，诺和诺德以每股836.80丹麦克朗的平均价格回购了824,500股B股，总额为689,940,585丹麦克朗。这些交易是2024年4月30日之前的计划回购的一部分，该期间的目标是21亿丹麦克朗。在这些收购之后，诺和诺德持有47,365,207亿股股票作为库存股，占股本的1.1％。该公司的悠久历史可以追溯到1923年，致力于抗击严重的慢性病，在80个国家拥有约63,400名员工。诺和诺德的股票在哥本哈根纳斯达克上市，其ADR在纽约证券交易所上市。
有用
没用